FDA approves Lilly's oral SERD combo for second-line breast cancer therapy

The FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, a regimen that includes Lilly’s oral selective estrogen receptor degrader (SERD) drug Inluriyo. Patients with metastatic ...